$34.60
-0.57-1.62%
À la fermeture: -
$34.60
0.000.00%
Après les heures de négociation: 4:18 PM EDT
Comments
Loading...
Orientation et prévision
Ultragenyx Pharmaceutical publie des prévisions sur le BPA et les revenus futurs, donnant aux investisseurs un aperçu du montant que la société s'attend à gagner au cours des prochaines périodes.
Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
08/05/2025 | RARE | Ultragenyx Pharmaceutical | FY | 2025 | — | — | — | $640.00M | $670.00M | $650.79M | |
05/06/2025 | RARE | Ultragenyx Pharmaceutical | FY | 2025 | — | — | — | $640.00M | $670.00M | $655.81M | |
02/13/2025 | RARE | Ultragenyx Pharmaceutical | FY | 2025 | — | — | — | $640.00M | $670.00M | $651.93M | |
01/12/2025 | RARE | Ultragenyx Pharmaceutical | FY | 2024 | — | — | — | $555.00M | $560.00M | $541.43M | |
01/12/2025 | RARE | Ultragenyx Pharmaceutical | FY | 2025 | — | — | — | $640.00M | $670.00M | $638.35M | |
11/05/2024 | RARE | Ultragenyx Pharmaceutical | FY | 2024 | — | — | — | $530.00M | $550.00M | $536.80M | |
08/01/2024 | RARE | Ultragenyx Pharmaceutical | FY | 2024 | — | — | — | $530.00M | $550.00M | $513.16M | |
05/02/2024 | RARE | Ultragenyx Pharmaceutical | FY | 2024 | — | — | — | $500.00M | $530.00M | $513.00M | |
02/15/2024 | RARE | Ultragenyx Pharmaceutical | FY | 2024 | — | — | — | $500.00M | $530.00M | $504.31M | |
01/08/2024 | RARE | Ultragenyx Pharmaceutical | FY | 2023 | — | — | — | $430.00M | $435.00M | $436.11M | |
01/08/2024 | RARE | Ultragenyx Pharmaceutical | FY | 2024 | — | — | — | $500.00M | $530.00M | $523.86M | |
11/02/2023 | RARE | Ultragenyx Pharmaceutical | FY | 2023 | — | — | — | $425.00M | $450.00M | $438.74M | |
10/16/2023 | RARE | Ultragenyx Pharmaceutical | Q3 | 2023 | — | — | — | $96.00M | $100.00M | $113.33M | |
08/03/2023 | RARE | Ultragenyx Pharmaceutical | FY | 2023 | — | — | — | $425.00M | $450.00M | $437.55M | |
05/04/2023 | RARE | Ultragenyx Pharmaceutical | FY | 2023 | — | — | — | $425.00M | $450.00M | $435.57M | |
02/16/2023 | RARE | Ultragenyx Pharmaceutical | FY | 2023 | — | — | — | $425.00M | $450.00M | $432.78M |
FAQ
Quelles sont les dernières directives pour Ultragenyx Pharmaceutical (RARE) ?
Il n'y a eu aucune orientation spécifique sur les ventes ou les bénéfices rapportée pour Ultragenyx Pharmaceutical ces derniers mois.
Parcourir guidance et prévisions sur toutes les actions.